Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Redefining pancreatic cancer management with tumor-agnostic precision medicine.

Carcinogenesis - 22 Nov 2024

Reddy Neha K, Subbiah Vivek

Abstract excerpt

Precision oncology and tumor-agnostic drug development provide hope for enhancing outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged across various tumor types, driven by insights into shared biomarkers. In the case of pancreatic cancer, the prevalence of the KRAS gene mutation is noteworthy. However, there exist other actionable alterations, such as BRCA1/2 mutations and fusion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to FGFR2 gene
Share to NRG1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Oncogene Proteins, Fusion

Share to Pancreatic Neoplasms

Share to Precision Medicine

Source

Identifiers

PMID: 39514550
DOI: 10.1093/carcin/bgae066

Genes

BRAF
FGFR2
KRAS
RET
ALK
BRCA1
NRG1
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Redefining pancreatic cancer management with tumor-agnostic precision medicine.PMID 39514550Read ↗

Targeted Therapies in Pancreatic Cancer: A New Era of Precision MedicineSemantic proximity Read ↗

Pancreatic cancer subtyping - the keystone of precision treatmentSemantic proximity Read ↗

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.Semantic proximity Read ↗

Moving the Needle on Precision Medicine in Pancreatic CancerSemantic proximity Read ↗

Precision oncology promise in the management of pancreatic acinar cell carcinoma.Semantic proximity Read ↗

Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities.Semantic proximity Read ↗

Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic CancerSemantic proximity Read ↗

A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.Semantic proximity Read ↗

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. PishvaianSemantic proximity Read ↗

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.Semantic proximity Read ↗

Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel OpportunitiesSemantic proximity Read ↗

Clinical utility of molecular subtyping of pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.